特发性膜性肾病中医临床实践指南（2021）

特发性膜性肾病占我国肾小球疾病的24.9%，已跃居第二位且比例有逐年增高趋势。中医药治疗已广泛应用于特发性膜性肾病的临床实践中，然而目前尚无中医治疗膜性肾病的循证实践指南。本指南按照国际指南制订方法与步骤，证据质量及推荐意见强度使用GRADE方法，通过访谈国医大师以及广东省名中医，确定指南范围、形成临床问题提纲；基于访谈结果和现有中西医肾病指南、权威教材以及临床研究文献的系统梳理和回顾的结果拟定临床问题、膜性肾病临床疗效评价指标以及中医证型的调查清单，在全国范围内进行专家调查；然后针对临床问题检索到的证据进行质量评价，并举行专家共识会议，最终形成关于中医治疗特发性膜性肾病的10条推荐意见。本指南聚焦于中医治疗特发性膜性肾病的临床实践，适用于各级中医/中西医结合医疗机构以及开展中医药服务的医疗机构及医务工作者。

Clinical Practice Guideline for Chinese Medicine in the Treatment of Idiopathic Membranous Nephropathy (2021)

In China, idiopathic membranous nephropathy (IMN) accounts for 24.9% of glomerular diseases, the second highest share, and is increasing year by year. Chinese medicine has been widely used in the clinical practice of IMN. However, there are no evidence-based practice guidelines for the treatment of IMN with Chinese medicine. This guideline followed the methods and steps of the guideline development manual. The level of the body of the evidence was assessed by the GRADE. An outline of the clinical questions was formulated through interviews with leading Chinese medicine experts and a review of relevant clinical guidelines. Based on the results of a systematic review of authoritative textbooks and clinical research literature, a clinical question list, a clinical outcome assessment index for IMN, and a list of types of Chinese medicine syndromes were developed, and a national expert survey was conducted to identify the clinical questions included in this guideline. A consensus meeting was held to finalize 10 recommendations for treating IMN with Chinese medicine. This guideline focuses on the clinical practice of Chinese medicine in the treatment of IMN, and is applicable to all levels of Chinese medicine and integrated Chinese and Western medicine institutions, as well as medical institutions and healthcare workers who provide Chinese medicine services.